EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Incremental Propensity Score Interventions: A Primer for Pharmacoepidemiologists

Byeong Yeob Choi iD

Pharmacoepidemiology and Drug Safety · 2026

DOI: 10.1002/pds.70484 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2026. Verfasst von Byeong Yeob Choi. Beteiligte Einrichtung: Department of Population Health Sciences, Long School of Medicine, UT San Antonio Health Science Center, San Antonio, Texas, USA. Hauptthemen laut MEDLINE: Propensity Score, Pharmacoepidemiology, Percutaneous Coronary Intervention, Immunoglobulin Fab Fragments. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In observational pharmacoepidemiology, estimating average treatment effects (ATEs) is often challenging due to a lack of practical positivity. In highly selective clinical settings, certain patients almost always or never receive treatment, causing ATE estimators to rely on unstable extrapolation. Incremental propensity score interventions (IPSIs) offer a stochastic alternative by shifting each patient's probability of treatment, providing a more clinically realistic framework that circumvents positivity violations.

Methods

We illustrate the IPSI approach, including key identification results and inferential procedures. Using observational data from a cohort of 996 patients undergoing percutaneous coronary intervention (PCI), we evaluated the effect of shifting each patient's probability of receiving abciximab by a predetermined amount on six‐month mortality. Propensity scores (PSs) and outcome predictions were estimated using a machine learning ensemble (Super Learner) with 10‐fold sample splitting.

Results

The ATE estimate suggested that abciximab administration reduced the 6‐month mortality risk by 5.9 percentage points compared with PCI alone (risk difference = −0.059, 95% CI: −0.104 to −0.015). However, the practical interpretability of the ATE estimate may be limited because it implicitly assumes that patients with a near‐certain probability of treatment could realistically be assigned to withhold abciximab. In contrast, shifting each patient's treatment propensity by odds ratios ranging from 0.1 to 10 showed that 6‐month mortality would be significantly reduced under a strong treatment policy promoting abciximab administration.

Conclusions

IPSIs provide a robust and practical alternative to conventional causal inference methods in pharmacoepidemiology settings where treatment assignment is highly selective and the strict positivity is violated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Propensity ScorePharmacoepidemiologyPercutaneous Coronary InterventionImmunoglobulin Fab FragmentsHumansAbciximabMachine LearningAntibodies, MonoclonalFemaleMaleCohort StudiesAgedPlatelet Aggregation InhibitorsTreatment OutcomeMiddle Aged

Stichwörter der Autor:innen

abciximabaverage treatment effectincremental propensity score interventionmachine learninguniform inference

Substanzen

AbciximabImmunoglobulin Fab FragmentsAntibodies, MonoclonalPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Department of Population Health Sciences, Long School of Medicine, UT San Antonio Health Science Center, San Antonio, Texas, USA.

ORCID-Profile: Byeong Yeob Choi

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Choi, B. Y. (2026). Incremental Propensity Score Interventions: A Primer for Pharmacoepidemiologists. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70484

Vancouver

Choi BY. Incremental Propensity Score Interventions: A Primer for Pharmacoepidemiologists. Pharmacoepidemiology and Drug Safety. 2026. doi:10.1002/pds.70484

BibTeX
@article{Choi2026,
  author = {Choi, Byeong Yeob},
  title = {Incremental Propensity Score Interventions: A Primer for Pharmacoepidemiologists},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2026},
  doi = {10.1002/pds.70484}
}
Kostenlos starten →